Does prolonged β-blocker use beyond 3 years post-MI improve long-term outcomes in elderly patients?
Prolonged beta-blocker therapy beyond 3 years post-MI in older adults does not appear to provide additional prognostic benefit.
In this observational analysis, β-blocker use beyond 3 years post-MI, regardless of the dose achieved, was not associated with improved outcomes. The role of prolonged β-blocker use, particularly in older adults, needs further investigation.
Shavadia et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: